Jade Biosciences Stock Forecast
NASDAQ: JBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 14.25 +0.71%
JBIO analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$50.13+254.28%
- Strong buy 0
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Jade Biosciences (2026-10-08), 10 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $50.13, with a high estimate of $77.00 and a low estimate of $40.00. The average target implies upside of 254.3% from the current price of $14.15.
The spread between the highest and lowest targets is 92.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for JBIO.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 10 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $40.00 | +182.69% |
| Average target | $50.13 | +254.28% |
| High target | $77.00 | +444.17% |